Alvotech Files Form 6-K with SEC
Ticker: ALVOW · Form: 6-K · Filed: Jul 11, 2024 · CIK: 1898416
| Field | Detail |
|---|---|
| Company | Alvotech (ALVOW) |
| Form Type | 6-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $965 million, $900 million, $65 million, $1,035 m, $185 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-private-issuer
TL;DR
Alvotech filed a 6-K, confirming its 20-F reporting and Luxembourg HQ.
AI Summary
Alvotech, a biopharmaceutical company, filed a Form 6-K on July 11, 2024. The filing is a report of a foreign private issuer and indicates that Alvotech files annual reports under Form 20-F. The company's principal executive office is located at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg.
Why It Matters
This filing provides routine disclosure for Alvotech as a foreign private issuer, informing investors about its reporting status and principal place of business.
Risk Assessment
Risk Level: low — This filing is a routine disclosure for a foreign private issuer and does not contain material new financial or operational information.
Key Players & Entities
- Alvotech (company) — Registrant
- 001-41421 (company) — SEC File Number
- 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg (company) — Principal executive office address
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Does Alvotech file annual reports under Form 20-F or 40-F?
Alvotech indicates it files annual reports under cover of Form 20-F.
What is Alvotech's principal executive office address?
Alvotech's principal executive office is located at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg.
What is the Commission File Number for Alvotech?
Alvotech's Commission File Number is 001-41421.
What is the SIC code for Alvotech?
Alvotech's Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-07-11 08:00:09
Key Financial Figures
- $965 million — ity (the "Facility"). The Facility, for $965 million in aggregate principal amount, matures
- $900 million — tranche of the Facility is a first lien $900 million term loan which bears an interest rate
- $65 million — The second tranche of the Facility is a $65 million first lien, second out term loan, which
- $1,035 m — has a total gross borrowings balance of $1,035 million, and cash balance of $185 million
- $185 m — of $1,035 million, and cash balance of $185 million, which includes $160 million cash
- $160 million — balance of $185 million, which includes $160 million cash on hand, of which $142 million is
- $142 million — des $160 million cash on hand, of which $142 million is the estimated net proceeds of the Fa
- $25 million — mated net proceeds of the Facility, and $25 million of restricted cash. A copy of the Press
Filing Documents
- f6k_071124.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-003881.txt ( ) — 19KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alvotech (Registrant) Date: July 11, 2024 /s/ Tanya Zharov Tanya Zharov General Counsel